Product Description
AMG 811is a human IgG1 monoclonal antibody that selectively targets and neutralizes human IFN- g.
Mechanisms of Action: IFNG Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Lupus Erythematosus, Discoid|Lupus Erythematosus, Cutaneous|Glomerulonephritis|Lupus Erythematosus, Systemic|Lupus Nephritis|Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00818948 | P1 |
Completed |
Lupus Erythematosus, Systemic|Lupus Nephritis|Glomerulonephritis |
2014-06-01 |
|
NCT01510951 | P1 |
Completed |
Psoriasis |
2012-10-01 |
|
NCT01164917 | P1 |
Terminated |
Lupus Erythematosus, Cutaneous|Lupus Erythematosus, Discoid|Lupus Erythematosus, Systemic |
2012-09-01 |
|
NCT02291588 | P1 |
Completed |
Lupus Erythematosus, Systemic |
2010-03-01 |